5Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement CLSI document, MIO0- S20. Chicago : CLSI, 2010. 被引量：1
6Zavascki AP, Carvalhaes CG, Picgo RC, et al. Mu|tidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy[J]. Expert Review of Anti-infective Therapy, 2010, 8(1): 71-93. 被引量：1
7Strateva T, Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance[J] Journal of Medical Microbiology, 2009, 58(Pt 9): 1133-1148. 被引量：1
8Skurnik M, Strauch E. Phage therapy: facts and fiction[J]. International Journal of Medical Microbiology: IJMM, 2006, 296(1): 5-14. 被引量：1
9Hawkins C, Harper D, Burch D, et al. Topical treatment ofPseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial[J]. Veterinary Microbiology, 2010, 146(3/4):309-313. 被引量：1
10Hendrix RW. Bacteriophage genomics[J]. Current opinion in microbiology 2003, 6(5):506-511. 被引量：1
